Anemocyte will participate in TIDES Europe 2025, taking place in Basel, Switzerland, from 11 to 13 November 2025.
The event represents one of Europe’s leading gatherings dedicated to oligonucleotide, peptide, and mRNA therapeutics, covering the entire value chain from discovery and process development to GMP manufacturing and commercialization.
TIDES Europe, organized by Informa Connect, brings together key stakeholders from biotechnology and pharmaceutical companies, CDMOs, regulatory agencies, and academic institutions to exchange insights on innovation, process optimization, and regulatory trends shaping the future of RNA-based medicines.
Anemocyte’s participation reflects its continued commitment to supporting the evolving landscape of nucleic acids-based therapies manufacturing, with a specific focus on plasmid DNA and mRNA research, development and production.
Attending TIDES Europe offers an important opportunity to connect with international partners, explore new collaborations, and contribute to discussions on scalability, regulatory compliance, and innovation within the RNA and oligonucleotide sector.
Anemocyte looks forward to meeting industry peers and partners in Basel to share perspectives and reinforce its positioning as a reference player in research, development andmanufacturing for nucleic acids-based therapies.
